
|Videos|August 13, 2021
Aurion Biotech: Treating endothelial disease with one donor
Author(s)David Hutton, Alex Delaney-Gesing
Edward Holland, MD, discusses Aurion Biotech's investigation of an injectable technique where one cornea donor could potentially supply hundreds of patients with treatment for endothelial disease.
Advertisement
Edward Holland, MD, chief medical advisor for Aurion Biotech, discusses the company's investigation of injectable endothelial cells, where one cornea donor could potentially supply hundreds of patients with treatment for endothelial disease as well as other forms of corneal edema.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ocular Therapeutix randomizes first patient in HELIOS-3
2
AAO 2025 Takeaways: How imaging and remote monitoring are transforming retinal care
3
Orasis Pharmaceuticals introduces starter packs of pilocarpine hydrochloride ophthalmic solution 0.4%
4
Regeneron's EYLEA HD injection 8 mg approved by FDA for the treatment of macular edema following RVO
5


















































.png)


